Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program
Rhea-AI Summary
Picard Medical (NYSE American: PMI), parent of SynCardia, announced publication of an independent commentary in peer-reviewed journal Artificial Organs on its next-generation Emperor total artificial heart platform, which integrates the Emperor Drive with the SynCardia Total Artificial Heart.
The article reviews total artificial heart history and recent preclinical large-animal implants of the “Emperor TAH.” According to Picard Medical, three acute implants were completed successfully, delivering stable full circulatory support with physiologic autoregulation and no device-related intraoperative failures. The commentary highlights the platform’s independent dual-motor design for separate systemic and pulmonary control and its potential to more closely replicate cardiac function without an external pneumatic driver. It also notes SynCardia’s two decades of clinical experience and that its Total Artificial Heart is the only commercially available device of this type approved in the U.S. and Canada. The publication states the piece is a news update and not an endorsement.
Positive
- Three successful acute large-animal implants with stable circulatory support and no device-related intraoperative failures
- Independent commentary in Artificial Organs highlights Emperor TAH as a milestone toward a fully implantable artificial heart
- Emperor platform’s dual-motor architecture enables independent systemic and pulmonary circulatory control
- SynCardia Total Artificial Heart remains the only commercially available TAH approved in both the U.S. and Canada
Negative
- Emperor platform remains in preclinical development; significant engineering, preclinical, and regulatory work still required before human evaluation
- Journal explicitly states the article is a news update, not an endorsement of the company or its products
Market reaction after Emperor TAH preclinical data commentary: PMI +6.52% in the Jul 16 session
In the Jul 16 session, PMI gained 6.52%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.5% during that session. Argus tracked a trough of -16.6% from its starting point during tracking. Our momentum scanner triggered 67 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 5.7x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 13 | Stockholder presentation | Positive | -7.5% | Annual meeting deck showing strong Q1 growth and Emperor platform milestones. |
| Jul 2 | Stockholder presentation | Positive | -1.6% | Updated presentation with 85% revenue growth and capital structure proposals. |
| Jun 24 | Leadership transition | Neutral | -2.5% | CEO resignation and appointment of chairman Richard Fang as interim CEO. |
| Jun 16 | Conference data preview | Positive | -3.9% | Planned ASAIO 2026 presentations on Emperor TAH in vivo data and outcomes. |
| Jun 2 | Preclinical implant data | Positive | +60.3% | Disclosure of three successful acute in vivo Emperor TAH animal implants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent PMI news often saw muted or negative price reactions even on operationally positive updates, with the early June preclinical implant data a notable bullish exception.
Key Terms
total artificial heart medical
preclinical medical
biventricular heart failure medical
dual-motor architecture technical
pneumatic driver technical
electromechanical drive system technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Peer-reviewed journal's News section highlights the Company’s continued progress toward a fully implantable total artificial heart
TUCSON, Ariz., July 15, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC (“SynCardia”), maker of the world's first and only total artificial heart approved by the U.S. Food and Drug Administration (“FDA”) and Health Canada, today announced the publication of an independent commentary in Artificial Organs examining the Company's next-generation Emperor platform, which combines the Emperor Drive with the SynCardia Total Artificial Heart (“STAH”), and its role in the continued evolution of mechanical heart replacement technology.
The article, titled “A New Chapter in the Quest for a Fully Implantable Artificial Heart”, was authored by Aakash M. Shah, M.D., an integrated cardiothoracic surgery resident at University of Texas Health Science Center at San Antonio (UT Health San Antonio) and lead editor of the News section of Artificial Organs. The commentary reviews the history of total artificial heart development and highlights the Company's recent preclinical studies of what the publication refers to as the “Emperor TAH” as another milestone in the pursuit of a fully implantable artificial heart.
The commentary discusses the latest series of acute large-animal implant studies evaluating the Company's next-generation Emperor platform. As previously announced by the Company, three implant procedures were completed successfully, with the device providing stable full circulatory support, demonstrating physiologic autoregulatory behavior, and experiencing no device-related intraoperative failures. The article also highlights the Emperor platform's independent dual-motor architecture, which enables independent control of the systemic and pulmonary circulations. The article explains how the design achieves a higher fidelity to closely replicate physiologic cardiac function while eliminating the need for an external pneumatic driver.
“The independent commentary published in Artificial Organs places the Emperor platform within the broader context of the decades-long effort to develop a practical, fully implantable artificial heart,” said Richard Fang, Ph.D., Interim Chief Executive Officer and Chairman of Picard Medical. “While significant work remains, we believe the successful acute implant studies represent an encouraging preclinical milestone. We remain focused on the engineering, preclinical, and regulatory work necessary to advance the Emperor platform toward human clinical evaluation.”
The commentary also reviews SynCardia's more than two decades of clinical experience in total artificial heart therapy, noting that the SynCardia Total Artificial Heart remains the only commercially available total artificial heart approved in both the United States and Canada. Within the Company's development program, this next-generation platform consists of the Emperor Drive, a electromechanical drive system under development, integrated with the STAH. Together, the platform is designed to provide independent control of the systemic and pulmonary circulations while building upon the proven pumping principles established through the SynCardia Total Artificial Heart.
The article concludes that continued advances in total artificial heart technology have the potential to expand future treatment options for patients with advanced biventricular heart failure who may not receive a donor heart, due to health conditions rendering the patient ineligible or a lack of supply. As stated by the publication, the article is intended as a news update for the journal's readership and does not constitute an endorsement of the Company.
Article Reference
Shah AM. A New Chapter in the Quest for a Fully Implantable Artificial Heart. Artificial Organs. 2026. doi:10.1111/aor.70182.
Read the article: https://onlinelibrary.wiley.com/doi/10.1111/aor.70182
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
Forward-looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on management’s current expectations, assumptions, and beliefs and involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Forward-looking statements can often be identified by words such as “anticipate,” “believe,” “continue,” “expect,” “goal,” “intend,” “may,” “plan,” “remain,” “target,” “will,” “advance,” “expand,” and similar expressions, and variations or negatives of these words.
These statements include, but are not limited to, statements regarding the Company’s financial condition, future operating results, commercialization activities, expectations for growth, expanding utilization of the SynCardia Total Artificial Heart, expanding patient access at transplant centers, supporting clinical partners, advancing development of the Emperor Total Artificial Heart and other next-generation technologies, regulatory submissions and approvals, manufacturing and supply chain initiatives, capital raising activities, strengthening the Company’s commercial and financial position, strategic initiatives, leadership transitions, and other statements that are not historical facts.
Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Factors that may cause such differences include, but are not limited to, risks relating to the Company’s ability to obtain additional financing, maintain compliance with applicable stock exchange listing requirements, achieve commercial adoption of its products, obtain regulatory approvals, execute manufacturing and supply chain initiatives, successfully develop next-generation technologies, manage market conditions, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission (”SEC”).
The Company expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained herein, whether as a result of new information, future events, changed circumstances, or otherwise, except as required by law.
Additional information about the Company, including risk factors that may affect the Company’s business, financial condition, and results of operations, is contained in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge at www.sec.gov and on the Company’s investor relations website at www.picardmedical.com.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
